Title

Lateral Flow Assay for Prostate Cancer Diagnosis

Description/Abstract/Artist Statement

Approximately 34,000 men in the United States lost their lives to prostate cancer (PCa) in 2021 according to the National Institutes of Health’s Cancer Institute. Making prostate cancer the second leading cause of death in American men. Prostate cancer diagnosis, often occurring in the later stages where survival rates are lower, is achieved with a core needle biopsy. This invasive procedure that tests for the prostate specific antigen, an antigen that when elevated is indicative of cancer, has a significant number of PCa false positives. Gold nanoparticles (AuNPs) selectivity and biocompatibility makes them ideal candidates for prostate cancer diagnosis. Here a lateral flow biosensor (LFB) assay is developed using AuNPs to diagnosis PCa. This LFB tests for oncogenic and tumor suppressor PCa-associated miRNAs. The developed LFB produced visual and numerical data to decrease the false positive rates in prostate cancer testing. This LFB has the potential to enable earlier diagnosis of prostate cancer and ultimately save lives.

Presenting Author Name/s

Taryn Amos

Faculty Advisor/Mentor

Gymama Slaughter, Alexis Moody

College Affiliation

College of Sciences

Presentation Type

Poster

Disciplines

Biochemistry | Chemistry

Session Title

Poster Session

Location

Learning Commons @ Perry Library

Start Date

3-19-2022 9:00 AM

End Date

3-19-2022 11:00 AM

This document is currently not available here.

Share

COinS
 
Mar 19th, 9:00 AM Mar 19th, 11:00 AM

Lateral Flow Assay for Prostate Cancer Diagnosis

Learning Commons @ Perry Library

Approximately 34,000 men in the United States lost their lives to prostate cancer (PCa) in 2021 according to the National Institutes of Health’s Cancer Institute. Making prostate cancer the second leading cause of death in American men. Prostate cancer diagnosis, often occurring in the later stages where survival rates are lower, is achieved with a core needle biopsy. This invasive procedure that tests for the prostate specific antigen, an antigen that when elevated is indicative of cancer, has a significant number of PCa false positives. Gold nanoparticles (AuNPs) selectivity and biocompatibility makes them ideal candidates for prostate cancer diagnosis. Here a lateral flow biosensor (LFB) assay is developed using AuNPs to diagnosis PCa. This LFB tests for oncogenic and tumor suppressor PCa-associated miRNAs. The developed LFB produced visual and numerical data to decrease the false positive rates in prostate cancer testing. This LFB has the potential to enable earlier diagnosis of prostate cancer and ultimately save lives.